Glaxo Wellcome Inc.

Other

Delta Pharmaceuticals Ltd.

Burroughs Wellcome Co.

Grady Evan Boswell

James L Kelley

Robert Anthony Mook

Kwen-Jen Chang

Roy A Swaringen, Jr

Eric C Bigham

John J Savarese

Robert Walton McNutt, Jr

Dulce Garrido Bubacz

Eric Eugene Boros

Ann O Davis

Sanjay Shashikant Patel

Vincente Samano

Mark Allan Collins

Nariman Bomanshaw Mehta

Timothy Mark Willson

Istvan Kaldor

David Lee Musso

David Norman Deaton

Matthew J Sharp

Jon Loren Collins

Barrett R Cooper

Marcus Brackeen

Brad Richard Henke

John Mark O'Callaghan

Jeffrey Edmond Cobb

Greg Alan Erickson

A compound having formula (I), wherein A is selected from the group consisting of: (i) phenyl, wherein said phenyl is optionally substituted by one or more halogen atoms, C,alkyl, C,alkoxy, C,fluoroalkoxy, nitrile, or &mdash;NR,R,where R,and R,are independently hydrogen or C,alkyl; (ii) a 5- or 6-membered hetrocyclic group containing at least one heteroatom selected from oxygen, nitrogen and sulfur; and (iii) a fused bicyclic ring (a), wherein ring C represents a heterocyclic group as defined in point (ii) above, which bicyclic ring is attached to group B via a ring atom of ring C; B is selected from the group consisting of: (iv) C,alkylene; (v) &mdash;MC,alkylene or C,alkyleneMC,alkylene, wherein M is O, S, or &mdash;NR,wherein R,represents hydrogen or C,alkyl; (vi) a 5- or 6-membered heterocyclic group containing at least one nitrogen heteroatom and optionally at least one further heteroatom selected from oxygen, nitrogen and sulfur and optionally substituted by C,alkyl; and (vii) Het-C,alkylene, wherein Het represents a heterocyclic group as defined in point (vi) above; Alk represents C,alkylene; R,represents hydrogen or C,alkyl; Z is selected from the group consisting of: (viii) &mdash;(C,alkylene) phenyl, which phenyl is optionally substituted by one or more halogen atoms; and (ix) &mdash;NR,R,, wherein R,represents hydrogen or C,alkyl, and R,represents &mdash;Y&mdash;(C&boxH;O)&mdash;T&mdash;R,, or &mdash;Y&mdash;(CH(OH))&mdash;T&mdash;R,.

Substituted 4-hydroxy-phenylalcanoic acid derivatives with agonist activity to PPAR-gamma

Ultrashort acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein: X is a halogen; h is from 1 to 2; Y is hydrogen or methoxy; Z,and Z,are methyl; W,and W,are carbon; and A is a pharmaceutically acceptable anion.

Substituted isoquinolines as ultra short acting neuromuscular blockers

Ultra short acting neuromuscular blocking agents of Formula (I) which are useful as skeletal muscle relaxants during emergency intubation procedures, routine surgery and post-operative settings are disclosed, wherein q and t are independently from 0 to 4; X,and X,are independently halogen; h,and h,are independenity from 0 to 2; Z,and Z,are indepentdently hydrogen, C,alkyl, C,alkenyl or C,alkynyl with the proviso that Z,and Z,are not both hydrogen; Y,, Y,, and Y,and Y,are independently hydrogen, halogen or C,alkoxy; m and p are independently 1 to 6; n and r are independently 0 to 4; with the proviso the if h,and h,are both 0, then r is 0 and n is 0 to 2; R,to R,are independently hydrogen, halogen, C,alkoxy, or R,and R,together with the carbon atoms to which they are bonded, R,and R,together with the carbon atoms to which they are bonded, R,and R,together with the carbon atoms to which they are bonded, R,and R,together with the carbon atoms to which they are bonded, may independently form a methylenedioxy or ethylenedioxy moiety contained in five- or six-membered ring; W,and W,are carbon; and A is a pharmaceutically acceptable anion.

A method for the treatment or prophylaxis of one or more conditions or disorders selected from the group consisting of physiological pain, diarrhea, urinary incontinence, mental illness, drug and alcohol addiction/overdose, lung edema, depressioysema, apnea, cognitive disorders and gastrointestinal disorders, comprising administration to a subject in need of such treatment or prophylaxis, of a diarylmethylpiperazine or piperidine opioid compound.

Opioid diarylmethylpiperazines and piperidines

Novel morpholines of formula (I) and their salts, wherein R and R1 are each either hydrogen or fluorine and R2 is hydrogen or methyl. The compounds have a variety of uses in human medicine, in particular in the treatment of mental disorders such as depression. ##STR1##

Arylmorpholine preparation and use

Opioid diarylmethylpiperazines and piperdines

A method for the treatment of depression in a human being, the method comprising administering to the human being an antidepressant effective amount of a compound of the following formula ##STR1## or a pharmaceutically acceptable salt thereof, wherein R and R.sup.1 are independently hydrogen or fluorine.

Arylmorpholine, preparation and use

Novel (2S, 3S, 5R) morpholinols of formula (I) ##STR1## together with the (+-)-(2R*,3R*,5S*) racemates thereof, and their salts, wherein

Heterocyclic pharmaceutical compounds and use

Growing community of inventors

Cary, NC, United States of America

Grady Evan Boswell